148 related articles for article (PubMed ID: 37791408)
1. Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study.
Grymonprez M; Carnoy L; Capiau A; Boussery K; Mehuys E; De Backer TL; Steurbaut S; Lahousse L
Eur Heart J Cardiovasc Pharmacother; 2023 Dec; 9(8):722-730. PubMed ID: 37791408
[TBL] [Abstract][Full Text] [Related]
2. Impact of P-glycoprotein and/or CYP3A4-interacting drugs on effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: A meta-analysis.
Grymonprez M; Vanspranghe K; Capiau A; Boussery K; Steurbaut S; Lahousse L
Br J Clin Pharmacol; 2022 Jul; 88(7):3039-3051. PubMed ID: 35132677
[TBL] [Abstract][Full Text] [Related]
3. Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation Using P-gp and/or CYP450-Interacting Drugs: a Systematic Review and Meta-analysis.
Grymonprez M; Vanspranghe K; Steurbaut S; De Backer TL; Lahousse L
Cardiovasc Drugs Ther; 2023 Aug; 37(4):781-791. PubMed ID: 34637052
[TBL] [Abstract][Full Text] [Related]
4. Impact of Polypharmacy and P-Glycoprotein- and CYP3A4-Modulating Drugs on Safety and Efficacy of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation.
Harskamp RE; Teichert M; Lucassen WAM; van Weert HCPM; Lopes RD
Cardiovasc Drugs Ther; 2019 Oct; 33(5):615-623. PubMed ID: 31520256
[TBL] [Abstract][Full Text] [Related]
5. Impact of frailty on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a nationwide cohort study.
Grymonprez M; Petrovic M; De Backer TL; Steurbaut S; Lahousse L
Eur Heart J Qual Care Clin Outcomes; 2024 Jan; 10(1):55-65. PubMed ID: 36941126
[TBL] [Abstract][Full Text] [Related]
6. Comparing the risk of dementia in subjects with atrial fibrillation using non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists: a Belgian nationwide cohort study.
Grymonprez M; Petrovic M; De Backer TL; Ikram MA; Steurbaut S; Lahousse L
Age Ageing; 2023 Mar; 52(3):. PubMed ID: 36934339
[TBL] [Abstract][Full Text] [Related]
7. Bleeding and thromboembolism due to drug-drug interactions with non-vitamin K antagonist oral anticoagulants-a Swedish, register-based cohort study in atrial fibrillation outpatients.
Holm J; Mannheimer B; Malmström RE; Eliasson E; Lindh JD
Eur J Clin Pharmacol; 2021 Mar; 77(3):409-419. PubMed ID: 33029651
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes in elderly atrial fibrillation patients at increased bleeding risk treated with very low dose vs. regular-dose non-vitamin K antagonist oral anticoagulants: a nationwide cohort study.
Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Yeh YH; Kuo CT; See LC; Lip GYH
Eur Heart J Cardiovasc Pharmacother; 2023 Dec; 9(8):681-691. PubMed ID: 37580139
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Polypharmacy on the Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation.
Grymonprez M; Petrovic M; De Backer TL; Steurbaut S; Lahousse L
Thromb Haemost; 2024 Feb; 124(2):135-148. PubMed ID: 37369234
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic Drug-Drug Interactions and Bleeding Outcomes in Patients with Atrial Fibrillation Using Non-Vitamin K Antagonist Oral Anticoagulants: a Nationwide Cohort Study.
Grymonprez M; Capiau A; Steurbaut S; Boussery K; Mehuys E; Somers A; Petrovic M; De Backer TL; Lahousse L
Cardiovasc Drugs Ther; 2023 Nov; ():. PubMed ID: 37930588
[TBL] [Abstract][Full Text] [Related]
11. Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation.
Chang SH; Chou IJ; Yeh YH; Chiou MJ; Wen MS; Kuo CT; See LC; Kuo CF
JAMA; 2017 Oct; 318(13):1250-1259. PubMed ID: 28973247
[TBL] [Abstract][Full Text] [Related]
12. Concurrent use of P-glycoprotein or Cytochrome 3A4 drugs and non-vitamin K antagonist oral anticoagulants in non-valvular atrial fibrillation.
Sandhu RK; Islam S; Dover DC; Andrade JG; Ezekowitz J; McAlister FA; Hawkins NM; Kaul P
Eur Heart J Qual Care Clin Outcomes; 2022 Mar; 8(2):195-201. PubMed ID: 33480405
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic profile and drug interactions with non-vitamin K antagonist oral anticoagulants: implications for patients with atrial fibrillation.
Xiong Q; Lau YC; Lip GY
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):937-48. PubMed ID: 25797167
[TBL] [Abstract][Full Text] [Related]
14. Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation.
Graham DJ; Baro E; Zhang R; Liao J; Wernecke M; Reichman ME; Hu M; Illoh O; Wei Y; Goulding MR; Chillarige Y; Southworth MR; MaCurdy TE; Kelman JA
Am J Med; 2019 May; 132(5):596-604.e11. PubMed ID: 30639551
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
16. Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study.
Staerk L; Gerds TA; Lip GYH; Ozenne B; Bonde AN; Lamberts M; Fosbøl EL; Torp-Pedersen C; Gislason GH; Olesen JB
J Intern Med; 2018 Jan; 283(1):45-55. PubMed ID: 28861925
[TBL] [Abstract][Full Text] [Related]
17. Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage.
Tsai CT; Liao JN; Chiang CE; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chung FP; Chao TF; Lip GYH; Chen SA
JAMA Netw Open; 2020 Jun; 3(6):e206424. PubMed ID: 32478848
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes in patients with atrial fibrillation and a history of falls using non-vitamin K antagonist oral anticoagulants: A nationwide cohort study.
Grymonprez M; Petrovic M; De Backer TL; Steurbaut S; Lahousse L
Int J Cardiol Heart Vasc; 2023 Aug; 47():101223. PubMed ID: 37252193
[TBL] [Abstract][Full Text] [Related]
19. Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban.
Stöllberger C; Finsterer J
Herz; 2015 Apr; 40 Suppl 2():140-5. PubMed ID: 25616425
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of secondary prevention of non-vitamin K oral anticoagulants use by drug type in Asian patients.
Nam KW; Kwon HM; Lee YS; Won SH; Moon HS
Int J Stroke; 2023 Oct; 18(8):927-936. PubMed ID: 37154599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]